Merck will acquire immune-focused Prometheus Biosciences for approximately $10.8 billion, scoring five clinical and pre-clinical candidates for inflammatory bowel and immune-mediated diseases.
https://www.pharmalive.com/wp-content/uploads/2023/04/BioSpaceMerck4-17-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-04-17 11:01:562023-04-17 11:19:58Merck leans into immunology with $10.8B Prometheus buy
